Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Ethical considerations in studying drug safety--the Institute of Medicine report.

Mello MM, Goodman SN, Faden RR.

N Engl J Med. 2012 Sep 6;367(10):959-64. doi: 10.1056/NEJMhle1207160. Epub 2012 Aug 22. No abstract available.

2.

IOM advises FDA on ethics in postmarket safety trials.

Kuehn BM.

JAMA. 2010 Aug 11;304(6):627. doi: 10.1001/jama.2010.1080. No abstract available.

PMID:
20699450
3.

Congress responds to the IOM drug safety report--in full.

Psaty BM, Korn D.

JAMA. 2007 Nov 14;298(18):2185-7. No abstract available.

PMID:
18000202
4.

The report of the Institute of Medicine on drug safety.

Somberg J.

Am J Ther. 2007 Jan-Feb;14(1):1-2. No abstract available.

PMID:
17303967
5.

Sidelining safety--the FDA's inadequate response to the IOM.

Smith SW.

N Engl J Med. 2007 Sep 6;357(10):960-3. No abstract available.

6.

The report by the Institute of Medicine and postmarketing surveillance.

Klein DF.

Arch Gen Psychiatry. 1999 Apr;56(4):353-4. No abstract available.

PMID:
10197831
7.

A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.

Psaty BM, Meslin EM, Breckenridge A.

JAMA. 2012 Jun 20;307(23):2491-2. doi: 10.1001/jama.2012.5545. No abstract available.

PMID:
22563032
8.

The future of drug safety: what the IOM report may mean to the emergency department.

Berger E.

Ann Emerg Med. 2007 Feb;49(2):193-5. No abstract available.

PMID:
17245837
9.

IOM panel hears concerns about U.S. drug safety system.

Young D.

Am J Health Syst Pharm. 2005 Jul 15;62(14):1428, 1430-31. No abstract available.

PMID:
15998915
10.

Protecting the health of the public--Institute of Medicine recommendations on drug safety.

Psaty BM, Burke SP.

N Engl J Med. 2006 Oct 26;355(17):1753-5. Epub 2006 Oct 9. No abstract available.

11.

The FDA and the IOM report.

Galson SK.

N Engl J Med. 2007 Dec 13;357(24):2520-1; author reply 2521-2. No abstract available.

12.

IOM urges FDA to be more aggressive in monitoring safety of approved drugs.

Kuehn BM.

JAMA. 2012 Jun 20;307(23):2475-6. doi: 10.1001/jama.2012.5993. No abstract available.

PMID:
22797430
13.

The FDA in 2006: reasons for optimism.

Chabner BA, Roberts TG.

Oncologist. 2007 Mar;12(3):247-9. No abstract available.

14.

Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.

Finkelstein JB.

J Natl Cancer Inst. 2007 Jan 17;99(2):104-7. No abstract available.

PMID:
17227990
15.

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.

Bunney WE Jr, Azarnoff DL, Brown BW Jr, Cancro R, Gibbons RD, Gillin JC, Hullett S, Killam KF, Kupfer DJ, Krystal JH, Stolley PD, French GS, Pope AM.

Arch Gen Psychiatry. 1999 Apr;56(4):349-52. No abstract available.

PMID:
10197830
16.

Sweeping changes, or a sweep under the rug?

Barie PS.

Surg Infect (Larchmt). 2006 Oct;7(5):407-8. No abstract available.

PMID:
17083306
17.

Conflict of Interest in Practice Guidelines Panels.

Sox HC.

JAMA. 2017 May 2;317(17):1739-1740. doi: 10.1001/jama.2017.2701. No abstract available.

PMID:
28464160
18.

Reply to "Can the Institute of Medicine review the FDA?".

Fineberg HV.

Nat Med. 2005 Jun;11(6):589. No abstract available.

PMID:
15937463
19.

Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.

Crawford LM.

Food Drug Law J. 2005;60(2):99-102. No abstract available.

PMID:
16097087
20.

FDA responds to institute of medicine drug safety recommendations--in part.

Psaty BM, Charo RA.

JAMA. 2007 May 2;297(17):1917-20. No abstract available.

PMID:
17473302

Supplemental Content

Support Center